Literature DB >> 599192

Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII.

G R Milner, P J Holt, J Bottomley, J E Maciver.   

Abstract

A patient is described who had an inhibitor to coagulation factor XIII associated with serum autoantibodies to certain tissues. The relationship of these abnormal findings to practolol therapy suggests that this was practolol-induced lupus erythematosus. Further investigations delineating the site of action of the inhibitor to factor XIII are reported.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 599192      PMCID： PMC476544          DOI： 10.1136/jcp.30.8.770

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  14 in total

1.  PLASMA FIBRIN STABILIZING FACTOR ACTIVITY IN VARIOUS DISEASES.

Authors:  M NUSSBAUM; B S MORSE
Journal:  Blood       Date:  1964-05       Impact factor: 22.113

2.  Circulating anticoagulants: a study of 40 cases and a review of the literature.

Authors:  A MARGOLIUS; D P JACKSON; O D RATNOFF
Journal:  Medicine (Baltimore)       Date:  1961-05       Impact factor: 1.889

3.  An acquired inhibitor to coagulation factor 13.

Authors:  J H Lewis; I L Szeto; L D Ellis; W L Bayer
Journal:  Johns Hopkins Med J       Date:  1967-06

4.  A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia.

Authors:  R D Rosenberg; R W Colman; L Lorand
Journal:  Br J Haematol       Date:  1974-02       Impact factor: 6.998

5.  Circulating anticoagulants against factors IX and XI in systemic lupus erythematosus.

Authors:  O Castro; L R Farber; L P Clyne
Journal:  Ann Intern Med       Date:  1972-10       Impact factor: 25.391

6.  An acquired inhibitor to factor XIII.

Authors:  N B McDevitt; J McDonagh; H L Taylor; H R Roberts
Journal:  Arch Intern Med       Date:  1972-11

7.  An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations.

Authors:  P T Otis; D I Feinstein; S I Rapaport; M J Patch
Journal:  Blood       Date:  1974-12       Impact factor: 22.113

8.  Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol).

Authors:  P Brown; H Baddeley; A E Read; J D Davies; J McGarry
Journal:  Lancet       Date:  1974-12-21       Impact factor: 79.321

9.  Circulating anticoagulants to factor VIII. Immunochemical studies and clinical response to factor VIII concentrates.

Authors:  S J Robboy; E J Lewis; P H Schur; R W Colman
Journal:  Am J Med       Date:  1970-12       Impact factor: 4.965

10.  Systemic lupus erythematosus syndrome induced by practolol.

Authors:  E B Raftery; A M Denman
Journal:  Br Med J       Date:  1973-05-26
View more
  6 in total

1.  Case report of an acquired factor XIII inhibitor: diagnosis and management.

Authors:  Thomas F Gregory; Barry Cooper
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-07

Review 2.  Acquired FXIII inhibitors: a systematic review.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

3.  Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis.

Authors:  Masatake Matsuoka; Tokifumi Majima; Tomohiro Onodera; Masahiro Ieko; Masayoshi Souri; Akitada Ichinose; Takashi Kurita; Yasuhiko Kasahara; Masahiro Inoue; Daisuke Takahashi
Journal:  Int J Hematol       Date:  2012-10-16       Impact factor: 2.490

Review 4.  Acetylator phenotype and lupus erythematosus.

Authors:  J P Uetrecht; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

5.  Nonhemophiliac musculoskeletal pseudotumor.

Authors:  Indrani Sen; Dheepak Selvaraj; Prabhu Premkumar; Sunil Agarwal
Journal:  J Vasc Surg Cases       Date:  2015-06-19

6.  New developments in the management of congenital Factor XIII deficiency.

Authors:  Zehra Fadoo; Quratulain Merchant; Karim Abdur Rehman
Journal:  J Blood Med       Date:  2013-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.